Leptomeningeal Carcinomatosis: Diagnosis and Management

Intracranial Metastases: Current Management Strategies

Volumn , Issue , 2008, Pages 309-330

  Groves, Morris D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Leptomeningeal carcinomatosis (LC); Malignancies; Neoplastic meningitis; Neurological deficits; Radiation

Indexed keywords

EID: 60849111658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753064.ch18     Document Type: Chapter

References (118)

1. Kaplan JG, DeSouza TG, Farkash A, et al.: Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9: 225-299.
2. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49: 759-772.
3. Olson ME, Chernik NL, Posner JB: Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974; 30: 122-377.
4. Balm M, Hammack J: Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch Neurol 1996; 53: 626-322.
5. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38: 51-77.
6. Glass JP, Melamed M, Chernik NL, et al.: Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29: 1369-1755.
7. Hitchins RN, Bell DR, Woods RL, et al.: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5:1655-1622.
8. Rosen ST, Aisner J, Makuch RW, et al.: Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine 1982; 61: 45-53.
9. Chamberlain MC, Kormanik P: Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998; 55: 506-512.
10. Amer MH, Al-Sarraf M, Baker LH, et al.: Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978; 42: 660-688.
11. Ersboll J, Schultz HB, Thomsen BL, et al.: Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 1985; 35:487-496.
12. Hoerni-Simon G, Suchaud JP, Eghbali H, et al.: Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. Oncology 1987; 44: 98-101.
13. Dekker AW, Elderson A, Punt K, et al.: Meningeal involvement in patients with acute nonlymphocytic leukemia. Incidence, management, and predictive factors. Cancer 1985; 56: 2078-2082.
14. Nugent JL, Bunn PAJ, Matthews MJ, et al.: CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 1979; 44: 1885-1893.
15. Redman BG, Tapazoglou E, Al-Sarraf M: Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature. Cancer 1986; 58: 2656-2661.
16. Weissman DE, Grossman SA: Simultaneous leptomeningeal and intramedullary spinal metastases in small cell lung carcinoma. Med Pediatr Oncol 1986; 14: 54-56.
17. Norris LK, Grossman SA, Olivi A: Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol 1997; 32: 215-223.
18. Price RA, Johnson WW: The central nervous system in childhood leukemia. I. The arachnoid. Cancer 1973; 31: 520-533.
19. Aroney RS, Dalley DN, Chan WK, et al.: Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981; 71: 26-32.
20. Boyle R, Thomas M, Adams JH: Diffuse involvement of the leptomeninges by tumouraa clinical and pathological study of 63 cases. Postgrad Med J 1980; 56: 149-158.
21. Yung WA, Horten BC, Shapiro WR: Meningeal gliomatosis: a review of 12 cases. Ann Neurol 1980; 8: 605-608.
22. Posner JB. Leptomeningeal metastases. In: Posner JB (ed): Neurologic Complications of Cancer. Philadelphia, F.A. Davis, 1995; pp. 143-171.
23. Glantz MJ, Cole BF, Glantz LK, et al.: Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82: 733-739.
24. Murray JJ, Greco FA, Wolff SN, et al.: Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983; 75:289-294.
25. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, et al.: Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 1989; 7: 57-63.
26. Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 1981; 38: 696-699.
27. van Oostenbrugge RJ, Twijnstra A: Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999; 53: 382-385.
28. Oschmann P, Kaps M, Volker J, et al.: Meningeal carcinomatosis: CSF cytology, immunocytochemistry and biochemical tumor markers. Acta Neurol Scand 1994; 89: 395-399.
29. Peterslund NA, Black FT, Geil JP, et al.: Beta-2-microglobulin in the cerebrospinal fluid of patients with infections of the central nervous system. Acta Neurol Scand 1989; 80: 579-583.
30. Chamberlain MC: Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998; 50: 1173-1175.
31. Jorda M, Ganjei-Azar P, Nadji M: Cytologic characteristics of meningeal carcinomatosis:increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55: 181-184.
32. Garson JA, Coakham HB, Kemshead JT, et al.: The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology. J Neurooncol 1985; 3: 165-171.
33. van Oostenbrugge RJ, Hopman AH, Arends JW, et al.: The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases. Neurology 1998; 51:906-908.
34. van Oostenbrugge RJ, Hopman AH, Lenders MH, et al.: Detection of malignant cells in cerebrospinal fluid using fluorescence in situ hybridization. J Neuropathol Exp Neurol 1997; 56: 743-748.
35. Sze G, Soletsky S, Bronen R, et al.: MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJR Am J Roentgenol 1989; 153:1039-1049.
36. Chamberlain MC, Sandy AD, Press GA: Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40:435-438.
37. Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5: 3394-3402.
38. Chamberlain MC, Kormanik P, Jaeckle KA, et al.: 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999; 52:216-217.
39. Glantz MJ, Hall WA, Cole BF, et al.: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75:2919-2931.
40. Rogers LR, Duchesneau PM, Nunez C, et al.: Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992; 42: 1239-1241.
41. Shapiro WR, Posner JB, Ushio Y, et al.: Treatment of meningeal neoplasms. Cancer Treat Rep 1977; 61: 733-743.
42. Grossman SA, Spence A: NCCN clinical practice guidelines for carcinomatous/lymphomatous meningitis. Oncology 1999; 13: 144-152.
43. Hanssens PE, Lagerwaard FJ, Levendag PC: Principles of radiotherapy of neoplastic meningosis. J Neurooncol 1998; 38: 145-150.
44. Bokstein F, Lossos A, Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998; 82: 1756-1763.
45. Glantz MJ, Cole BF, Recht L, et al.: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16: 1561-1567.
46. Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161-166.
47. Bleyer WA, Poplack DG: Intraventricular versus intralumbar methotrexate for centralnervous- system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979; 6: 207-213.
48. Haghbin M, Galicich JH: Use of the Ommaya reservoir in the prevention and treatment of CNS leukemia. Am J Pediatr Hematol Oncol 1979; 1: 111-117.
49. Chamberlain MC: Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998; 37: 271-284.
50. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:561-569.
51. Sause WT, Crowley J, Eyre HJ, et al.: Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastasesaa Southwest Oncology Group study. J Neurooncol 1988; 6: 107-112.
52. Gutin PH, Weiss HD, Wiernik PH, et al.: Intrathecal N, N′, N″-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study. Cancer 1976; 38: 1471-1475.
53. Chamberlain MC, Khatibi S, Kim JC, et al.: Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 1993; 50: 261-264.
54. Chamberlain MC, Kormanik P, Howell SB, et al.: Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995; 52: 912-917.
55. Kim S, Chatelut E, Kim JC, et al.: Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186-2193.
56. Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110-3116.
57. Trump DL, Grossman SA, Thompson G, et al.: Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 1982; 66: 1549-1551.
58. Giannone L, Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986; 4: 68-73.
59. Stewart DJ, Maroun JA, Hugenholtz H, et al.: Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies. J Neurooncol 1987; 5: 315-322.
60. Sampson JH, Archer GE, Villavicencio AT, et al.: Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999; 5: 1183-1188.
61. Blaney SM, Cole DE, Balis FM, et al.: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993; 53: 725-727.
62. Blaney SM, Cole DE, Godwin K, et al.: Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995; 36: 121-124.
63. Blaney S, Balis F, Murphy R, et al.: A phase I study of intrathecal mafosfamide in patients with refractory meningeal malignancies. Proceedings of the American Society of Clinical Oncology 1993; 34: Abstract.
64. Slavc I, Schuller E, Czech T, et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998; 38: 213-218.
65. Schold SCJ, Mahaley MSJ, Vick NA, et al.: Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. J Clin Oncol 1987; 5:464-471.
66. Zimm S, Collins JM, Curt GA, et al.: Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res 1984; 44:1698-1701.
67. Berg SL, Balis FM, Zimm S, et al.: Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992; 10: 143-148.
68. Huang TY, Arita N, Hayakawa T, et al.: ACNU, MTX and 5-FU penetration of rat brain tissue and tumors. J Neurooncol 1999; 45: 9-17.
69. Levin VA, Chamberlain M, Silver P, et al.: Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 1989; 23:301-307.
70. Ushio Y, Kochi M, Kitamura I, et al.: Ventriculolumbar perfusion of 3-[(4-amino-2- methyl-5-pyrimidinyl)-methyl]-1-(2-chloroethyl-1-nitrosourea hydrochloride for subarachnoid dissemination of gliomas. J Neurooncol 1998; 38: 207-212.
71. Gunther R, Chelstrom LM, Tuel-Ahlgren L, et al.: Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 1995; 85: 2537-2545.
72. Myklebust AT, Godal A, Fodstad O: Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Res 1994; 54:2146-2150.
73. Hall WA, Myklebust A, Godal A, et al.: In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery 1994; 34:649-655.
74. Archer GE, Sampson JH, Lorimer IA, et al.: Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 1999; 5: 2646-2652.
75. Laske DW, Muraszko KM, Oldfield EH, et al.: Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 1997; 41: 1039-1049.
76. Moseley RP, Benjamin JC, Ashpole RD, et al.: Carcinomatous meningitis: antibodyguided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry 1991; 54: 260-265.
77. Moseley RP, Papanastassiou V, Zalutsky MR, et al.: Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 1992; 52:38-43.
78. Bigner DD, Brown M, Coleman RE, et al.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies antitenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2aa preliminary report. J Neurooncol 1995; 24: 109-122.
79. Papanastassiou V, Pizer BL, Chandler CL, et al.: Pharmacokinetics and dose estimates following intrathecal administration of 131I-monoclonal antibodies for the treatment of central nervous system malignancies. Int J Radiat Oncol Biol Phys 1995; 31: 541-552.
80. Kemshead JT, Hopkins K, Pizer B, et al.: Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies. Br J Cancer 1998; 77: 2324-2330.
81. Coakham HB, Kemshead JT: Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 1998; 38: 225-232.
82. Kramer K, Cheung NK, Humm JL, et al.: Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol 2000; 35: 716-718.
83. Moser R, Bruner JM, Grimm EA: Biologic therapy for brain tumors. Cancer Bull 1991; 43:117-126.
84. Okamoto Y, Shimizu K, Tamura K, et al.: An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 1988; 94: 47-52.
85. Shimizu K, Okamoto Y, Miyao Y, et al.: Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 1987; 66: 519-521.
86. Silvani A, Salmaggi A, Parmiani G, et al.: Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report. Neurosurgery 1994; 34: 1078-1080.
87. Salmaggi A, Dufour A, Silvani A, et al.: Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules. Ital J Neurol Sci 1996; 17: 267-276.
88. Ram Z, Walbridge S, Oshiro EM, et al.: Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 1994; 54: 2141-2145.
89. Vrionis FD, Wu JK, Qi P, et al.: Tumor cells expressing the herpes simplex virus-thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats. J Neurosurg 1996; 84: 250-257.
90. Viola JJ, Ram Z, Walbridge S, et al.: Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. J Neurosurg 1995; 82: 70-76.
91. Rosenfeld MR, Bergman I, Schramm L, et al.: Adeno-associated viral vector gene transfer into leptomeningeal xenografts. J Neurooncol 1997; 34: 139-144.
92. Siegal T, Sandbank U, Gabizon A, et al.: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J Neurooncol 1987; 4: 233-242.
93. Grant R, Naylor B, Greenberg HS, et al.: Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994; 51: 457-461.
94. Boogerd W, Hart AA, van der Sande JJ, et al.: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991; 67: 1685-1695.
95. Jayson GC, Howell A, Harris M, et al.: Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 1994; 74: 3135-3141.
96. Zachariah B, Zachariah SB, Varghese R, et al.: Carcinomatous meningitis: clinical manifestations and management. Int J Clin Pharmacol Ther 1995; 33: 7-12.
97. Tetef ML, Margolin KA, Doroshow JH, et al.: Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000; 46: 19-26.
98. Friedman HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol 2000; 27(3 Suppl 6): 35-40.
99. Raymond E, Izbicka E, Soda H, et al.: Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3: 1769-1774.
100. Marzolini C, Decosterd LA, Shen F, et al.: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 1998; 42: 433-440.
101. Boogerd W, Dorresteijn LD, van Der Sande JJ, et al.: Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000; 55: 117-119.
102. Chamberlain MC, Kormanik PA, Barba D: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694-699.
103. Wolff L, Zighelboim J, Gale RP: Paraplegia following intrathecal cytosine arabinoside. Cancer 1979; 43: 83-85.
104. Marmont AM, Damasio EE: Letter: Neurotoxicity of intrathecal chemotherapy for leukaemia. Br Med J 1973; 4: 47.
105. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973; 289: 770-773.
106. Bleyer WA: Current status of intrathecal chemotherapy for human meningeal neoplasms. Natl Cancer Inst Monogr 1977; 46: 171-178.
107. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463-1469.
108. Friedberg MH, Glantz MJ, Klempner MS, et al.: Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998; 82: 923-930.
109. Mareel M, Leroy A, Bracke M: Cellular and molecular mechanisms of metastasis as applied to carcinomatous meningitis. J Neurooncol 1998; 38: 97-102.
110. Fizazi K, Asselain B, Vincent-Salomon A, et al.: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996; 77: 1315-1323.
111. Clamon G, Doebbeling B: Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement. Breast Cancer Res Treat 1987; 9: 213-217.
112. Yap HY, Yap BS, Rasmussen S, et al.: Treatment for meningeal carcinomatosis in breast cancer. Cancer 1982; 50: 219-222.
113. Ongerboer de Visser BW, Somers R, Nooyen WH, et al.: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 1983; 33: 1565-1572.
114. Pfeffer MR, Wygoda M, Siegal T: Leptomeningeal metastasesatreatment results in 98 consecutive patients. Isr J Med Sci 1988; 24: 611-618.
115. Young RC, Howser DM, Anderson T, et al.: Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med 1979; 66: 435-443.
116. MacKintosh FR, Colby TV, Podolsky WJ, et al.: Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982; 49: 586-595.
117. Recht L, Straus DJ, Cirrincione C, et al.: Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988; 84: 425-435.
118. Liang RH, Woo EK, Yu YL, et al.: Central nervous system involvement in non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1989; 25: 703-710.